1. Home
  2. AVDL vs DLY Comparison

AVDL vs DLY Comparison

Compare AVDL & DLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • DLY
  • Stock Information
  • Founded
  • AVDL 2015
  • DLY 2019
  • Country
  • AVDL Ireland
  • DLY United States
  • Employees
  • AVDL N/A
  • DLY N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • DLY Investment Managers
  • Sector
  • AVDL Health Care
  • DLY Finance
  • Exchange
  • AVDL Nasdaq
  • DLY Nasdaq
  • Market Cap
  • AVDL 861.4M
  • DLY 759.6M
  • IPO Year
  • AVDL 1996
  • DLY N/A
  • Fundamental
  • Price
  • AVDL $10.83
  • DLY $15.40
  • Analyst Decision
  • AVDL Strong Buy
  • DLY
  • Analyst Count
  • AVDL 7
  • DLY 0
  • Target Price
  • AVDL $18.71
  • DLY N/A
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • DLY 215.9K
  • Earning Date
  • AVDL 08-07-2025
  • DLY 01-01-0001
  • Dividend Yield
  • AVDL N/A
  • DLY 8.93%
  • EPS Growth
  • AVDL N/A
  • DLY N/A
  • EPS
  • AVDL N/A
  • DLY N/A
  • Revenue
  • AVDL $194,450,000.00
  • DLY N/A
  • Revenue This Year
  • AVDL $56.86
  • DLY N/A
  • Revenue Next Year
  • AVDL $30.45
  • DLY N/A
  • P/E Ratio
  • AVDL N/A
  • DLY N/A
  • Revenue Growth
  • AVDL 252.64
  • DLY N/A
  • 52 Week Low
  • AVDL $6.38
  • DLY $13.26
  • 52 Week High
  • AVDL $17.30
  • DLY $15.95
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 72.02
  • DLY 45.52
  • Support Level
  • AVDL $8.74
  • DLY $15.33
  • Resistance Level
  • AVDL $9.56
  • DLY $15.51
  • Average True Range (ATR)
  • AVDL 0.41
  • DLY 0.09
  • MACD
  • AVDL 0.18
  • DLY -0.01
  • Stochastic Oscillator
  • AVDL 89.88
  • DLY 33.93

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest

DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.

Share on Social Networks: